Voyager Therapeutics, Inc. (VYGR)

Nasdaq: VYGR · Biological Products, (No Diagnostic Substances) · Lexington, MA · filing with the SEC since 2015

Full chart Alerts Compare

Grade5.4

◀ Past 6.1● Present 5.6▶ Future 4.3

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$40.4M-49.5%

Net income-$120M-84.2%

Earnings per share$-2.04-80.5%

Operating cash flow-$132M-765.2%

Cash$65.3M-8.5%

Debtn/a

Shareholders’ equity$196M-34.6%

Shares, diluted58.7M+1.8%

Return on equity-61.1%

The recordfrom its filings

Filings in 202671

Newest filingNov 5 · 8-K

Annual reportMar 9, 2026

Quarterly reportNov 5, 2026

Next report due10-K by Mar 16

Insider sales, 12 months$300,000

Insider buys, 12 months$0.00

Patents granted42

Filer categoryAccelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $25.1MNet income -$105MCash from operations -$109Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 21, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 6, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Aug 6, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Jul 31, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Jul 13, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Voyager Therapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Lexington, MA.

Newest on the record

Current report on Nov 5. Before it, quarterly report on Nov 5.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 16, 2027.

About VYGR

Voyager Therapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Lexington, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $40 million and a loss of $120 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersLexington, MA

Business modelProduct business

ExchangeNasdaq

Filing since2015

Fiscal year endsDec 31

SEC number (CIK)1640266

Peers on fileMGTX, IVVD, AGEN, IPSC

Who runs it

Financial performance

In fiscal 2025 Voyager Therapeutics’s revenue was $40.37 million, down 49.5% from $80.00 million the year before. It made a net loss of $119.7 million.

Annual report, filed Mar 9, 2026.

Financial statements

The grade

Voyager Therapeutics grades 5.4 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past6.1

● Present5.6

▶ Future4.3

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton VYGR · research, not advice